Ayako Shiraki Selected Research

Neoplasms (Cancer)

3/2018	Intermediate-grade mammary gland adenocarcinoma in an 18-year-old female black leopard (Panthera pardus) with acute pancreatic necrosis and chronic interstitial nephropathy.
3/2017	Pulmonary neuroendocrine tumor in a female wolf (Canis lupus lupus).
3/2013	Direct progression of capsular invasive carcinomas from subcapsular focal hyperplasias induced by hypothyroidism-mediated tumor promotion in a rat two-stage thyroid carcinogenesis model.
1/2013	Enhanced liver tumor promotion activity in rats subjected to combined administration of phenobarbital and orphenadrine.
1/2013	Liver tumor promoting effect of orphenadrine in rats and its possible mechanism of action including CAR activation and oxidative stress.
1/2013	Suppressive effect of liver tumor-promoting activities in rats subjected to combined administration of phenobarbital and piperonyl butoxide.
6/2012	Complex apocrine carcinoma with dominant myoepithelial proliferation in a dog.
5/2012	High-grade myofibroblastic sarcoma of inguinal region in a dog.
1/2012	Liver tumor promoting effect of etofenprox in rats and its possible mechanism of action.
1/2012	Promoting effects of carminic acid-enriched cochineal extracts on capsular invasive thyroid carcinomas through targeting activation of angiogenesis in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ayako Shiraki Research Topics

Disease

10	Neoplasms (Cancer) 03/2018 - 01/2012
3	Hypothyroidism 11/2016 - 10/2012
3	Body Weight (Weight, Body) 01/2016 - 01/2012
1	Microcephaly 05/2014
1	Carcinogenesis 03/2013
1	Carcinoma (Carcinomatosis) 03/2013
1	Thyroid Neoplasms (Thyroid Cancer) 01/2012
1	Malnutrition (Nutritional Deficiencies) 01/2012

Drug/Important Bio-Agent (IBA)

3	Propylthiouracil FDA Link 11/2016 - 03/2013
3	Phenobarbital (Luminal)FDA Link 01/2013 - 06/2012
2	Keratins (Keratin)IBA 03/2018 - 03/2017
2	SulfadimethoxineIBA 03/2013 - 01/2012
2	Orphenadrine (Disipal)FDA LinkGeneric 01/2013 - 01/2013
2	Drinking WaterIBA 10/2012 - 01/2012
1	Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA 03/2017
1	Chromogranin AIBA 03/2017
1	Proliferating Cell Nuclear Antigen (PCNA)IBA 03/2017
1	Thyroid HormonesIBA 08/2014
1	Alkylating AgentsIBA 05/2014
1	Methylnitrosourea (N-Methyl-N-nitrosourea)IBA 05/2014
1	alpha-benzoylamino-1,4-naphthoquinone (PPM 18)IBA 07/2013
1	Extracellular Matrix ProteinsIBA 03/2013
1	TenascinIBA 03/2013
1	Antithyroid Agents (Antithyroid Drugs)IBA 03/2013
1	diisopropanolnitrosamineIBA 03/2013
1	Piperonyl Butoxide FDA Link 01/2013
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 01/2013
1	ParvalbuminsIBA 10/2012
1	Methimazole (Thiamazole)FDA LinkGeneric 10/2012
1	gamma-Aminobutyric Acid (GABA)IBA 10/2012
1	Aminobutyrates (Aminobutyric Acid)IBA 10/2012
1	Calbindin 2IBA 10/2012
1	VimentinIBA 05/2012
1	CalponinsIBA 05/2012
1	DesminIBA 05/2012
1	CollagenIBA 05/2012
1	Carmine (Natural Red 4)IBA 01/2012
1	androstaneIBA 01/2012
1	NitrosaminesIBA 01/2012
1	InsecticidesIBA 01/2012
1	Pyrethrins (Pyrethroids)FDA Link 01/2012
1	Proteins (Proteins, Gene)FDA Link 01/2012
1	ethofenprox (Trebon)IBA 01/2012
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 01/2012

Therapy/Procedure

2	Intraperitoneal Injections 01/2012 - 01/2012
1	Injections 01/2012